Stoke Therapeutics (NASDAQ: STOK) awards options and RSUs to counsel

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Allan Jonathan, received new equity awards. On February 17, 2026, he was granted an option to buy 53,000 shares of common stock at an exercise price of $0.00 per share and 35,000 restricted stock units (RSUs).

The option vests as to 1/48 of the total award on March 15, 2026, with an additional 1/48 vesting on each monthly anniversary, as long as he continues serving the company. Each RSU represents the right to receive one share of common stock, with the RSU award vesting in four equal annual installments beginning on February 15, 2027, also subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Allan Jonathan

Role GENERAL COUNSEL & CORP SEC

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	53,000	$0.00	--
Grant/Award	Restricted Stock Units	35,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 53,000 shares (Direct); Restricted Stock Units — 35,000 shares (Direct)

Footnotes (1)

1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$31.09	02/17/2026		A		53,000		(1)	02/16/2036	Common Stock	53,000	$0	53,000	D
Restricted Stock Units	(2)	02/17/2026		A		35,000		(3)	02/15/2030	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

3. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

	/s/ Jonathan Allan	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Allan Jonathan receive at Stoke Therapeutics (STOK)?

Allan Jonathan received two equity awards: an option to purchase 53,000 shares of Stoke Therapeutics common stock and a grant of 35,000 restricted stock units. Both awards were granted as part of his compensation in his role as General Counsel and Corporate Secretary.

How do the new stock options for Allan Jonathan at STOK vest?

The stock option for 53,000 shares vests over four years, with 1/48 of the total award vesting on March 15, 2026. Another 1/48 then vests on each monthly anniversary, contingent on Allan Jonathan’s continued service with Stoke Therapeutics.

What are the vesting terms for Allan Jonathan’s RSUs at Stoke Therapeutics?

The 35,000 restricted stock units vest in four equal annual installments. One-quarter of the RSUs will vest each year, with the first tranche vesting on February 15, 2027, provided Allan Jonathan remains in continuous service with Stoke Therapeutics through each vesting date.

What does each RSU granted to Allan Jonathan at STOK represent?

Each restricted stock unit represents a contingent right to receive one share of Stoke Therapeutics common stock upon settlement. The actual delivery of shares occurs as the RSUs vest, assuming Allan Jonathan continues to meet the service-based vesting conditions.

Is Allan Jonathan’s Form 4 transaction at Stoke Therapeutics a buy or a grant?

The Form 4 reflects equity grants, not open-market purchases. Both the 53,000-share stock option and 35,000 RSUs were acquired through award grants from Stoke Therapeutics as compensation, with no cash purchase price reported for these awards.